Related references
Note: Only part of the references are listed.Avoiding collider bias in Mendelian randomization when performing stratified analyses
Claudia Coscia et al.
EUROPEAN JOURNAL OF EPIDEMIOLOGY (2022)
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Stephen J. Nicholls et al.
NATURE MEDICINE (2022)
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
Florian Kronenberg et al.
EUROPEAN HEART JOURNAL (2022)
A sex-specific evolutionary interaction between ADCY9 and CETP
Isabel Gamache et al.
ELIFE (2021)
Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank
Joseph D. Szustakowski et al.
NATURE GENETICS (2021)
Exon 9-deleted CETP inhibits full length-CETP synthesis and promotes cellular triglyceride storage
Lahoucine Izem et al.
JOURNAL OF LIPID RESEARCH (2020)
Evaluating drug targets through human loss-of-function genetic variation
Eric Vallabh Minikel et al.
NATURE (2020)
Genetic drug target validation using Mendelian randomisation
Amand F. Schmidt et al.
NATURE COMMUNICATIONS (2020)
Effect of Anacetrapib on Cholesterol Efflux Capacity: A Substudy of the DEFINE Trial
Mark P. Metzinger et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2020)
Mendelian randomization reveals unexpected effects of CETP on the lipoprotein profile
Lisanne L. Blauw et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2019)
Lipoprotein signatures of cholesteryl ester transfer protein and HMG-CoA reductase inhibition
Johannes Kettunen et al.
PLOS BIOLOGY (2019)
Are drug targets with genetic support twice as likely to be approved? Revised estimates of the impact of genetic support for drug mechanisms on the probability of drug approval
Emily A. King et al.
PLOS GENETICS (2019)
Women in clinical trials: a review of policy development and health equity in the Canadian context
Alla Yakerson
INTERNATIONAL JOURNAL FOR EQUITY IN HEALTH (2019)
Mendelian randomization analysis of cholesteryl ester transfer protein and subclinical atherosclerosis: A population-based study
Tim Christen et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk
Benoit J. Arsenault et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2018)
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Neil M. Davies et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians
Neil M. Davies et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies A Mendelian Randomization Analysis
Stephen Burgess et al.
JAMA CARDIOLOGY (2018)
Variants at the APOE/C1/C2/C4 Locus Modulate Cholesterol Efflux Capacity Independently of High-Density Lipoprotein Cholesterol
Cecile Low-Kam et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Gender specific effect of CETP rs708272 polymorphism on lipid and atherogenic index of plasma levels but not on the risk of coronary artery disease A case-control study
Gaojun Cai et al.
MEDICINE (2018)
The UK Biobank resource with deep phenotyping and genomic data
Clare Bycroft et al.
NATURE (2018)
CETP (Cholesteryl Ester Transfer Protein) Concentration A Genome-Wide Association Study Followed by Mendelian Randomization on Coronary Artery Disease
Lisanne L. Blauw et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)
Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
Brian A. Ference et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Sex Differences in Blood HDL-c, the Total Cholesterol/HDL-c Ratio, and Palmitoleic Acid are Not Associated with Variants in Common Candidate Genes
Shannon L. Klingel et al.
LIPIDS (2017)
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease
A. Michael Lincoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
CETP (Cholesteryl Ester Transfer Protein) Inhibition With Anacetrapib Decreases Production of Lipoprotein(a) in Mildly Hypercholesterolemic Subjects
Tiffany Thomas et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2017)
Serum CETP concentration is not associated with measures of body fat: The NEO study
Lisanne L. Blauw et al.
ATHEROSCLEROSIS (2016)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
Hidenori Arai et al.
ATHEROSCLEROSIS (2016)
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance With Clinical Outcomes
Jean-Claude Tardif et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Genome-wide study for circulating metabolites identifies 62 loci and reveals novel systemic effects of LPA
Johannes Kettunen et al.
NATURE COMMUNICATIONS (2016)
Genotype-Dependent Effects of Dalcetrapib on Cholesterol Efflux and Inflammation Concordance With Clinical Outcomes
Jean-Claude Tardif et al.
CIRCULATION-CARDIOVASCULAR GENETICS (2016)
Plasma Cholesteryl Ester Transfer Protein Is Predominantly Derived From Kupffer Cells
Yanan Wang et al.
HEPATOLOGY (2015)
The support of human genetic evidence for approved drug indications
Matthew R. Nelson et al.
NATURE GENETICS (2015)
Adiposity significantly modifies genetic risk for dyslipidemia
Christopher B. Cole et al.
JOURNAL OF LIPID RESEARCH (2014)
Using Multivariable Mendelian Randomization to Disentangle the Causal Effects of Lipid Fractions
Stephen Burgess et al.
PLOS ONE (2014)
Genetic Determination of Plasma Cholesterol Efflux Capacity Is Gender-Specific and Independent of HDL-Cholesterol Levels
Elise F. Villard et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Cholesteryl Ester Transfer Protein (CETP) Polymorphisms Affect mRNA Splicing, HDL Levels, and Sex-Dependent Cardiovascular Risk
Audrey C. Papp et al.
PLOS ONE (2012)
Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
Amit V. Khera et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Representation of Women in Randomized Clinical Trials of Cardiovascular Disease Prevention
Chiara Melloni et al.
CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES (2010)
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport
Eric J. Niesor et al.
JOURNAL OF LIPID RESEARCH (2010)
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease.
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
Daniel Bloomfield et al.
AMERICAN HEART JOURNAL (2009)
Sex-associated effect of CETP and LPL polymorphisms on postprandial lipids in familial hypercholesterolaemia
Katherine K. Anagnostopoulou et al.
LIPIDS IN HEALTH AND DISEASE (2009)
Cellular SR-BI and ABCA1-mediated cholesterol efflux are gender-specific in healthy subjects
Giovanna Catalano et al.
JOURNAL OF LIPID RESEARCH (2008)
Possible role for intracellular cholesteryl ester transfer protein in adipocyte lipid metabolism and storage
Lahoucine Izem et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Cholesteryl ester-transfer protein (CETP) polymorphism and the association of acute coronary syndromes by obesity status in Greek subjects: The CARDIO2000-GENE study
George V. Dedoussis et al.
HUMAN HEREDITY (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Cholesteryl ester transfer protein promoter single-nucleotide polymorphisms in Sp1-binding sites affect transcription and are associated with high-density lipoprotein cholesterol
JF Thompson et al.
CLINICAL GENETICS (2004)
Taq1B CETP polymorphism, plasma CETP, lipoproteins, apolipoproteins and sex differences in a Jewish population sample characterized by low HDL-cholesterol
JD Kark et al.
ATHEROSCLEROSIS (2000)
Share Paper
